Results 21 to 30 of about 499,108 (302)

Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors

Haematologica, 2013
There have been few reports of a response to dasatinib or nilotinib after failure of two prior sequential tyrosine kinase inhibitors. We report the outcome of 82 chronic phase patients who received nilotinib or dasatinib as third-line alternative ...
Antonella Russo Rossi, Massimo Breccia, Elisabetta Abruzzese, Fausto Castagnetti, Luigiana Luciano, Antonella Gozzini, Mario Annunziata, Bruno Martino, Fabio Stagno, Francesco Cavazzini, Mario Tiribelli, Giuseppe Visani, Patrizia Pregno, Pellegrino Musto, Carmen Fava, Nicola Sgherza, Francesco Albano, Gianantonio Rosti, Giuliana Alimena, Giorgina Specchia   +19 more
doaj   +1 more source

Essential Role of Lyn in Fibrosis. [PDF]

, 2016
Fibrotic disorders involve replacement of normal parenchyma with myofibroblasts, which deposit connective tissue, leading to obliteration of the function of the underlying organ.
Birtolo, Chiara, Chheda, Chintan, Cirulli, Vincenzo, Gugliotta, Gabriele, Lewis, Michael S, Liu, Sandy T, Pandol, Stephen J, Pham, Hung, Ptasznik, Andrzej, Rodriguez, Maria D, Yang, Wendy   +10 more
core   +2 more sources

Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. [PDF]

, 2014
Btk and Etk/BMX are Tec-family non-receptor tyrosine kinases. Btk has previously been reported to be expressed primarily in B cells and has an important role in immune responses and B-cell malignancies.
Bhardwaj, G, Changou, C, Chintapalli, S, Evans, CP, Guo, W, Kumaresan, P, Kung, H-J, Lam, KS, Liu, R, Ma, A-H, Mazloom, A, Patterson, R, Sanchez, E, Xiao, K, Xiao, W, Yang, JC, Yeh, C-T   +16 more
core   +2 more sources

Tyrosine kinase inhibitor Tofacitinib. Safety issues

Медицинский совет, 2015
Tofacitinib (TOFA) was the first synthetic small molecule drug which was comparable with genetically engineered biological agents (GIBA) in terms of its therapeutic effect in rheumatoid arthritis (RA).
G. V. Lukina, Y. A. Sigidin
doaj   +1 more source

The nucleotide and partial amino acid sequences of rat fetuin [PDF]

, 1992
Fetuins are among the major plasma proteins, yet their biological role has remained elusive. Here we report the molecular cloning of rat fetuin and the sequence analysis of a full-length clone, RF619 of 1456 bp with an open reading frame of 1056 bp ...
Albrecht G. J., Brown W. M., Cam A., Cayatte A. J., Christie D. L., Cohen P., Colclasure G. C., Coughlin J. P., Davis L. G., Dziegielewska K. M., Dziegielewska K. M., Dziegielewska K. M., Edge A. S. B., Haasemann M., Heijne G., Hortin G., Jones S. E., Kellermann J., Laemmli U. K., Lee C. C., Lewis J. G., Mizuno M., Mollgard K., Muller-Esterl W., Oss C. J., Pedersen K. O., Puck T. T., Rawlings N. D., Rohrlich S. T., Sambrook J., Sanger F., Sbraccia P., Schultze H. E., Strauss E. C., Triffitt J. T., Yang F., Yet M. G.   +36 more
core   +1 more source

Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML [PDF]

, 2014
Pharmacological targeting of BTK using ibrutinib has recently shown encouraging clinical activity in a range of lymphoid malignancies. Recently we reported that ibrutinib inhibits human acute myeloid leukemia (AML) blast proliferation and leukemic cell ...
Bowles, Kristian M, Lawes, Matthew J, MacEwan, David J, Murray, Megan Y, Rushworth, Stuart A, Shafat, Manar S., Zaitseva, Lyubov   +6 more
core   +5 more sources

Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms

Haematologica, 2017
Nearly one-third of patients with acute myeloid leukemia have FMS-like tyrosine kinase 3 mutations and thus have poor survival prospects. Receptor tyrosine kinase anexelekto is critical for FMS-like tyrosine kinase 3 signaling and participates in FMS ...
Peter P. Ruvolo, Huaxian Ma, Vivian R. Ruvolo, Xiaorui Zhang, Hong Mu, Wendy Schober, Ivonne Hernandez, Miguel Gallardo, Joseph D. Khoury, Jorge Cortes, Michael Andreeff, Sean M. Post   +11 more
doaj   +1 more source

Lichen planopilaris-like eruption during treatment with tyrosine kinase inhibitor nilotinib [PDF]

Anais Brasileiros de Dermatologia, 2016
Tyrosine kinase inhibitors are effective as a target therapy for malignant neoplasms. Imatinib was the first tyrosine kinase inhibitor used. After its introduction, several other drugs have appeared with a similar mechanism of action, but less prone to ...
Juliana Ribeiro Leitão, Neusa Yuriko Sakai Valente, Priscila Kakizaki, Isis Suga Veronez, Mario Cezar Pires   +4 more
doaj   +1 more source

Nanomedicine of tyrosine kinase inhibitors

Theranostics, 2021
Recent progress in nanomedicine and targeted therapy brings new breeze into the field of therapeutic applications of tyrosine kinase inhibitors (TKIs). These drugs are known for many side effects due to non-targeted mechanism of action that negatively impact quality of patients' lives or that are responsible for failure of the drugs in clinical trials.
Šmídová, Veronika, Michálek, Petr, Goliášová, Zita, Eckschlager, Tomáš, Hodek, Petr, Adam, Vojtěch, Heger, Zbyněk   +6 more
openaire   +3 more sources

Rapamycin induces transactivation of the EGFR and increases cell survival. [PDF]

, 2009
The mammalian target of rapamycin (mTOR) signaling network regulates cell growth, proliferation and cell survival. Deregulated activation of this pathway is a common event in diverse human diseases such as cancers, cardiac hypertrophy, vascular ...
Chaturvedi, D, Cohen, MS, Gao, X, Patel, TB, Taunton, J   +4 more
core   +2 more sources